JP2024533153A5 - - Google Patents
Info
- Publication number
- JP2024533153A5 JP2024533153A5 JP2024513893A JP2024513893A JP2024533153A5 JP 2024533153 A5 JP2024533153 A5 JP 2024533153A5 JP 2024513893 A JP2024513893 A JP 2024513893A JP 2024513893 A JP2024513893 A JP 2024513893A JP 2024533153 A5 JP2024533153 A5 JP 2024533153A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- dual agonist
- patient
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21194879.9 | 2021-09-03 | ||
| EP21194879 | 2021-09-03 | ||
| EP22160234 | 2022-03-04 | ||
| EP22160234.5 | 2022-03-04 | ||
| PCT/EP2022/074420 WO2023031380A1 (en) | 2021-09-03 | 2022-09-02 | Dosage regime |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533153A JP2024533153A (ja) | 2024-09-12 |
| JP2024533153A5 true JP2024533153A5 (enExample) | 2024-10-09 |
Family
ID=84272918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513893A Pending JP2024533153A (ja) | 2021-09-03 | 2022-09-02 | 投薬レジーム |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250073311A1 (enExample) |
| EP (1) | EP4392054A1 (enExample) |
| JP (1) | JP2024533153A (enExample) |
| KR (1) | KR20240058121A (enExample) |
| AU (1) | AU2022339044A1 (enExample) |
| CA (1) | CA3228429A1 (enExample) |
| CL (1) | CL2024000647A1 (enExample) |
| IL (1) | IL311166A (enExample) |
| MX (1) | MX2024002600A (enExample) |
| TW (1) | TW202315882A (enExample) |
| WO (1) | WO2023031380A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025248124A1 (en) | 2024-05-31 | 2025-12-04 | Zealand Pharma A/S | Dapiglutide for use in treating a sub-group of subjects |
| WO2026052859A1 (en) | 2024-09-09 | 2026-03-12 | Zealand Pharma A/S | Treatment with dapiglutide |
| WO2026052861A1 (en) | 2024-09-09 | 2026-03-12 | Zealand Pharma A/S | Treatment with dapiglutide |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| AU723268B2 (en) | 1996-09-09 | 2000-08-24 | Zealand Pharma A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CZ20013018A3 (cs) | 1999-03-17 | 2002-02-13 | Novo Nordisk A/S | Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina |
| EP3551651B1 (en) | 2016-12-09 | 2024-03-06 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| WO2018104558A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| CA3044915A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| SG11202111311WA (en) | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| US20230129788A1 (en) * | 2020-03-30 | 2023-04-27 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
| IL301892A (en) * | 2020-12-16 | 2023-06-01 | Zealand Pharma As | Drug composition of dual GLP-1/GLP-2 agonists |
| MX2023006280A (es) * | 2020-12-16 | 2023-06-13 | Zealand Pharma As | Composicion farmaceutica de agonistas duales de glp-1/glp-2. |
| CA3200526A1 (en) * | 2020-12-16 | 2022-06-23 | Jesper Skodborg VILLADSEN | Pharmaceutical composition of glp-1/glp-2 dual agonists |
-
2022
- 2022-09-02 JP JP2024513893A patent/JP2024533153A/ja active Pending
- 2022-09-02 WO PCT/EP2022/074420 patent/WO2023031380A1/en not_active Ceased
- 2022-09-02 CA CA3228429A patent/CA3228429A1/en active Pending
- 2022-09-02 TW TW111133296A patent/TW202315882A/zh unknown
- 2022-09-02 MX MX2024002600A patent/MX2024002600A/es unknown
- 2022-09-02 IL IL311166A patent/IL311166A/en unknown
- 2022-09-02 EP EP22805777.4A patent/EP4392054A1/en active Pending
- 2022-09-02 KR KR1020247010163A patent/KR20240058121A/ko active Pending
- 2022-09-02 AU AU2022339044A patent/AU2022339044A1/en active Pending
- 2022-09-02 US US18/688,026 patent/US20250073311A1/en active Pending
-
2024
- 2024-03-01 CL CL2024000647A patent/CL2024000647A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024533153A5 (enExample) | ||
| JP6491174B2 (ja) | ニタゾキサニドの制御放出医薬配合物 | |
| JP2023002544A5 (enExample) | ||
| RU2007125259A (ru) | Способ и устройство для введения адреналина | |
| JP2004504406A5 (enExample) | ||
| RU2011139643A (ru) | Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты | |
| JP2007515469A5 (enExample) | ||
| CN1271287A (zh) | 布地奈德和福莫特罗的新用途 | |
| RU2002127804A (ru) | Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения | |
| RU2013119938A (ru) | Фармацевтическая композиция | |
| MXPA03010731A (es) | Combinacion de agonista del receptor a2a de adenosina y tiotropio o sus derivados para tratar enfermedades obstructivas de vias aereas. | |
| JP2006513184A5 (enExample) | ||
| JP2017533972A5 (enExample) | ||
| CN1512885A (zh) | 药物组合 | |
| CN101068571A (zh) | 改善透粘膜给药制剂的吸收的方法 | |
| RU2007101695A (ru) | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения | |
| EP3678643B1 (en) | Sublingual epinephrine tablets | |
| TWI341728B (en) | Combinations comprising epothilones and anti-metabolites | |
| JP2023502053A5 (enExample) | ||
| RU2543635C2 (ru) | Способ и фармацевтические композиции для лечения постпрандиальной гипергликемии диабета ii типа введением через слизистую ротовой полости | |
| Galanello | Iron chelation: new therapies | |
| CN1863512A (zh) | 控释药物组合物及其制备方法 | |
| US7998973B2 (en) | Tivozanib and temsirolimus in combination | |
| JP2004506605A5 (enExample) | ||
| CN110327362B (zh) | 次黄嘌呤核苷酸在制备抗抑郁药物中的应用 |